MONTELIN-LA TABLETS
Generic Name: Montelukast + Levocetirizine + Ambroxol
Composition: Montelukast 10 mg + Levocetirizine 10 mg + Ambroxol 10 mg .
Dosage Form: Oral Tablet
Drug Classification: Leukotriene Receptor Antagonist + Antihistamine + Mucolytic Agent
PRODUCT DESCRIPTION
MONTELIN-LA Tablets are a combination formulation intended to support the management of selected allergic respiratory conditions accompanied by mucus production. Montelukast blocks leukotriene receptors involved in airway inflammation, levocetirizine blocks histamine H1 receptors to relieve allergic symptoms, and ambroxol helps loosen and clear respiratory mucus. The combination targets allergic symptoms and mucus-related discomfort through complementary pharmacological actions.
INDICATIONS
Depending on the verified formulation and local product approval, this combination may be prescribed for selected allergic respiratory conditions accompanied by productive cough or thick mucus. The appropriate indication depends on the patient's diagnosis and clinical assessment.
MECHANISM OF ACTION
Montelukast selectively blocks cysteinyl leukotriene type 1 receptors, helping reduce leukotriene-mediated airway inflammation and bronchoconstriction. Levocetirizine is a selective peripheral H1-receptor antagonist that helps relieve sneezing, runny nose, itching, and other histamine-mediated allergic symptoms. Ambroxol is a mucolytic agent that helps reduce mucus viscosity and supports mucociliary clearance.
CLINICAL BENEFITS
MONTELIN-LA combines three complementary actions: leukotriene receptor blockade, antihistamine activity, and mucus management. When the combination is appropriate for the patient's condition, it may help relieve allergic nasal symptoms and support the clearance of thick respiratory secretions. Treatment should be selected according to the verified ingredients, strengths, and clinical indication.
KEY BENEFITS
• Helps relieve selected allergy-related symptoms.
• Targets leukotriene-mediated respiratory inflammation.
• Supports mucus clearance by reducing secretion viscosity.
• Combines complementary pharmacological actions in one oral formulation.
• Offers convenient oral administration when prescribed appropriately.
DOSAGE AND ADMINISTRATION
Use only according to the verified product label and healthcare professional's instructions. The dose and duration depend on the confirmed composition, patient age, diagnosis, and clinical response. Do not assume that the stated strengths are appropriate for every patient.
POSSIBLE SIDE EFFECTS
Possible adverse effects may include headache, drowsiness, dizziness, dry mouth, nausea, abdominal discomfort, or other gastrointestinal symptoms. Montelukast has been associated with serious neuropsychiatric effects, including changes in mood or behavior, sleep disturbances, depression, and suicidal thoughts or behavior. Seek prompt medical advice if unusual mood or behavioral changes occur.
CONTRAINDICATIONS AND PRECAUTIONS
Avoid use in patients with known hypersensitivity to any of the active ingredients or formulation components. Use cautiously in patients with kidney or liver impairment, depending on the confirmed formulation and prescribing information. Levocetirizine may cause drowsiness, so caution is advised when driving or operating machinery. Montelukast is not a rescue treatment for acute asthma attacks.
DRUG INTERACTIONS
Inform the healthcare professional about all medicines being taken. Sedatives and alcohol may increase drowsiness associated with levocetirizine. Other medicines may affect the safety or effectiveness of individual ingredients. A medication review is recommended before treatment.
USE DURING PREGNANCY
Use during pregnancy only when considered necessary by a healthcare professional after an individualized assessment of potential benefits and risks.
USE DURING BREASTFEEDING
Consult a healthcare professional before use during breastfeeding to assess the suitability of the complete combination and the potential risks to the infant.
Company: LINCOLN